期刊
CASE REPORTS IN ONCOLOGY
卷 10, 期 2, 页码 683-688出版社
KARGER
DOI: 10.1159/000479148
关键词
Interstitial lung disease; Nanoparticle albumin-bound paclitaxel; Non-small cell lung cancer; Single-agent treatment
类别
资金
- Grants-in-Aid for Scientific Research [15K08657] Funding Source: KAKEN
Interstitial lung disease (ILD) is a serious and potentially fatal adverse event in lung cancer therapy. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel, solvent-free formulation of paclitaxel (PTX). Although the incidence of nab-PTX-induced ILD is not clear, it is generally considered that this formulation presents a similar risk of developing ILD as PTX. Here, we report 3 patients who developed severe ILD following treatment with nab-PTX. We draw attention to the risk of developing drug-induced ILD following nab-PTX treatment, and highlight that this novel formulation might therefore not be as safe as PTX with respect to the development of ILD. (C) 2017 The Author(s) Published by S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据